CSL (CSL) AI Stock Analysis

• Market Cap: $99.20B
• Dividend Yield: 2.27%
• Average Volume (3M): 1.33M
• Price to Earnings (P/E): 21.4
• Beta (1Y): 0.74
• Revenue Growth: 6.07%
• EPS Growth: 13.75%
• Country: AU
• Employees: 32,698
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 3.52
• Shares Outstanding: 485,151,400
• 10 Day Avg. Volume: 1,166,609
• 30 Day Avg. Volume: 1,333,984
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.35
• Enterprise Value/Revenue: 8.94
• Enterprise Value/Gross Profit: 18.20
• Enterprise Value/Ebitda: 26.90
• 1Y Price Target: $281.80
• Price Target Upside: 40.15% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 13

• Rating: 73 Outperform
• Price Target: AU$232.00 ▲(15.38% Upside)

CSL's overall stock score is driven by strong financial performance and positive earnings call highlights, including revenue growth and strategic initiatives. However, bearish technical indicators and competitive challenges in key markets temper the outlook.

CSL Business Overview & Revenue Model

Company Description

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

How the Company Makes Money

CSL makes money primarily through the development, manufacturing, and sale of biotherapies and vaccines. CSL Behring, the company's largest segment, generates revenue from the sale of plasma-derived therapies and recombinant therapies, which are used to treat conditions such as hemophilia, primary immune deficiencies, and hereditary angioedema. Seqirus contributes to CSL's revenue by producing and selling influenza vaccines to healthcare providers globally. Key revenue streams stem from ongoing innovation, a diverse product portfolio, strategic acquisitions, and long-term partnerships with healthcare providers and governments to secure supply agreements. Additionally, CSL invests in research and development to continuously enhance its product offerings and maintain its position in the biotechnology industry.

CSL Financial Statement Overview

Summary

CSL exhibits consistent revenue growth and robust profitability with a stable balance sheet. However, rising debt levels and volatile cash flow present risks that need monitoring.

Income Statement

CSL has demonstrated consistent revenue growth over the years, highlighted by a strong revenue increase from 2020 to 2023. Gross profit margins have remained robust, reflecting effective cost management. However, the EBIT margin has shown some volatility, indicating fluctuations in operational efficiency. The net profit margin is healthy, but has slightly decreased in the most recent period, suggesting increased expenses or cost pressures.

Balance Sheet

The balance sheet shows a strong equity position, with a growing stockholders' equity over the years. The debt-to-equity ratio is relatively moderate, suggesting a balanced capital structure. However, the total debt has increased significantly, which could pose potential risk if not managed properly. The equity ratio remains stable, indicating financial stability, but the rising debt warrants careful monitoring.

Cash Flow

CSL has maintained positive free cash flow, reflecting the company's ability to generate cash after capital expenditures. However, the free cash flow growth rate has been inconsistent, with notable fluctuations. The operating cash flow to net income ratio is healthy, indicating good cash generation relative to profits. The variability in free cash flow suggests potential challenges in managing capital expenditures efficiently.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	14.98B	15.43B	14.69B	13.17B	10.49B	10.33B
Gross Profit	7.36B	7.95B	7.56B	6.71B	5.66B	5.80B
EBITDA	4.98B	5.13B	4.73B	3.90B	3.46B	2.72B
Net Income	3.12B	3.00B	2.64B	2.19B	2.25B	2.39B
Balance Sheet
Total Assets	38.45B	39.40B	38.02B	54.43B	41.22B	18.16B
Cash, Cash Equivalents and Short-Term Investments	1.52B	2.16B	1.66B	2.33B	15.18B	1.81B
Total Debt	11.96B	11.50B	12.18B	18.37B	14.04B	5.81B
Total Liabilities	17.90B	18.00B	18.62B	27.65B	20.02B	9.74B
Stockholders Equity	18.56B	19.34B	17.33B	23.72B	21.20B	8.38B
Cash Flow
Free Cash Flow	2.03B	2.54B	1.51B	1.35B	1.90B	1.97B
Operating Cash Flow	2.97B	3.56B	2.81B	3.87B	3.62B	3.65B
Investing Cash Flow	-924.09M	-850.00M	-1.26B	-17.61B	-2.26B	-1.68B
Financing Cash Flow	-1.43B	-2.24B	-1.28B	677.92M	10.58B	-1.41B

CSL Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 201.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CSL, the sentiment is Negative. The current price of 201.07 is below the 20-day moving average (MA) of 209.21, below the 50-day MA of 237.56, and below the 200-day MA of 249.59, indicating a bearish trend. The MACD of -9.87 indicates Negative momentum. The RSI at 28.89 is Positive, neither overbought nor oversold. The STOCH value of 9.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CSL.

CSL Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NEU	78 Outperform	2.48B	16.82	0.00%	―	12.35%	26.73%
CUV	77 Outperform	593.46M	15.56	15.02%	0.42%	7.76%	1.55%
CSL	73 Outperform	$99.20B	21.35	16.36%	2.27%	6.07%	13.75%
TLX	66 Neutral	4.71B	279.52	8.79%	―	60.23%	-66.98%
MSB	51 Neutral	2.94B	-17.61	-17.10%	―	198.58%	3.97%
IMM	50 Neutral	359.63M	-5.81	0.00%	―	0.00%	-19.21%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

CSL Corporate Events

CSL Limited Announces Cessation of Securities

CSL Limited announced the cessation of 7,194 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact CSL’s issued capital structure and reflects the company’s ongoing adjustments to its financial and operational strategies.

The most recent analyst rating on (AU:CSL) stock is a Buy with a A$325.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.

CSL’s ANDEMBRY® Gains FDA Approval for Hereditary Angioedema Treatment

CSL has announced the FDA approval of ANDEMBRY®, a groundbreaking treatment for hereditary angioedema (HAE), marking its immediate launch in the United States. This approval enhances CSL’s market positioning, offering the first and only prophylactic treatment targeting factor XIIa for HAE, with significant efficacy demonstrated in clinical trials. The treatment’s approval in multiple regions, including the EU and Japan, underscores its global impact and potential benefits for patients, stakeholders, and the company’s operations.

The most recent analyst rating on (AU:CSL) stock is a Buy with a A$325.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.

CSL Limited Appoints Cameron Price as Non-executive Director

CSL Limited has announced the appointment of Mr. Cameron Price as an independent Non-executive Director, effective October 1, 2025. Mr. Price brings extensive experience from his previous role as General Counsel & Chief Risk Officer at Australia’s Future Fund and his background in mergers & acquisitions and corporate governance. His appointment is expected to enhance CSL’s board with his insights and commercial acumen, potentially strengthening the company’s strategic positioning in global investment markets.

The most recent analyst rating on (AU:CSL) stock is a Buy with a A$310.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.

CSL Limited Announces Cessation of Securities

CSL Limited announced the cessation of 8,790 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This cessation reflects a specific adjustment in the company’s issued capital, potentially impacting shareholder value and market perception of the company’s securities management.

The most recent analyst rating on (AU:CSL) stock is a Buy with a A$310.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.

CSL Limited Announces Cessation of Securities

CSL Limited announced the cessation of 12,039 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could have implications for stakeholders regarding the company’s strategic financial management.